Loading...
Market
Number of new HAE patients prescribed donidalorsen by end of 2024?
5
Resolution / Starting Odds
0-500 • 25%
501-1000 • 25%
1001-1500 • 25%
1501+ • 25%
Healthcare data providers, prescription databases
Story
Ionis Reports Positive Results for Donidalorsen in OASIS-HAE and OASISplus Trials
May 31, 2024, 03:02 PM
Ionis Pharmaceuticals has announced positive results from two late-stage trials, OASIS-HAE and OASISplus, for its investigational therapy donidalorsen in treating hereditary angioedema (HAE). The trials demonstrated that donidalorsen, which targets prekallikrein mRNA, significantly reduced the attack rate in patients compared to a placebo. These benefits were observed even in patients currently on other HAE medications. $IONS (-1.0% pre).
View original story
Similar markets
Less than 10,000 • 25%
10,000 to 20,000 • 25%
20,001 to 30,000 • 25%
More than 30,000 • 25%
Below 10 • 33%
10 - 50 • 33%
Above 50 • 34%
Remains 9 • 25%
10 to 12 • 25%
13 to 15 • 25%
More than 15 • 25%
0-5 trials • 33%
6-10 trials • 33%
More than 10 trials • 34%